Quarterly ResultMay 7, 2026, 04:09 PM
Aldeyra Therapeutics Repays $15M Hercules Debt, Reduces Q1 Net Loss
AI Summary
Aldeyra Therapeutics reported a significantly reduced net loss of $3.45 million for the three months ended March 31, 2026, compared to $9.93 million in the prior year, driven by lower R&D and G&A expenses. Post-period, the company fully repaid and terminated its $15 million Hercules Credit Facility on April 1, 2026. The company also noted the cessation of development for its Helio Product Candidate, ADX-2191, in 2024, and anticipates needing additional funding for future activities.
Key Highlights
- Aldeyra repaid and terminated $15.0 million Hercules Credit Facility on April 1, 2026.
- Q1 2026 net loss significantly reduced to $(3.45) million from $(9.93) million year-over-year.
- Q1 2026 net loss per share improved to $(0.06) from $(0.17) year-over-year.
- Research and development expenses decreased to $2.41 million from $7.42 million year-over-year.
- General and administrative expenses fell to $1.14 million from $3.00 million year-over-year.
- Cash and cash equivalents were $65.00 million as of March 31, 2026.
- Company ceased development of ADX-2191 (Helio Product Candidate) in 2024.
- Management believes current cash is sufficient for 12 months, but additional funding is needed.